Introduction
============

Yolk sac tumors, also known as endodermal sinus tumors, and trophoblastic neoplasms are both malignant germ cell tumors. Producing alfa-fetoprotein and human chorionic gonadotropin (hCG), respectively, yolk sac tumors and trophoblastic neoplasms are strongly suggested by elevated serum alfa-fetoprotein and hCG levels.

Primary yolk sac tumors of the endometrium are extremely rare; to our knowledge, only nine cases have been reported in the literature,[@b1-ott-6-1515]--[@b9-ott-6-1515] among which only two cases are in coexistence with endometrial carcinomas. Endometrial carcinomas with trophoblastic differentiation are also very rare, with only 17 cases in the literature.[@b10-ott-6-1515]--[@b24-ott-6-1515] Despite being uncommon, such cases have a distinct prognosis from pure endometrial adenocarcinoma. These two groups of cases do not share an intersection set. However, we report a case of endometrial carcinoma with yolk sac tumor-like differentiation, as well as elevated serum level of the beta-subunit of hCG (β-hCG), which suggests trophoblastic differentiation although there is a lack of histologic evidence. A dramatic postoperative reduction of β-hCG further supports the existence of a trophoblastic component.

Case report
===========

A 28-year-old, nulligravid, married Chinese woman presented in December 2010 with a 14-month history of abnormal vaginal bleeding. The patient had been on barrier contraception, and to her knowledge had never been pregnant. Past medical history included epilepsy and hypothyroidism due to thyroidectomy. In October 2010, a diagnostic curettage specimen revealed endometrial adenocarcinoma with glandular squamous metaplasia, and an exploratory laparotomy was performed in a local hospital. A large omental mass and diffuse miliary nodules in the pelvic peritoneum made exposure of the surgical field difficult, so biopsy of the mass and peritoneum only was performed and histologic examination showed endometrial adenocarcinoma with yolk sac tumor-like differentiation. Chemotherapy, including intravenous paclitaxel 120 mg, adriamycin 60 mg, and intraperitoneal cisplatin 150 mg for one course, was administered at the local hospital. The patient was then referred to our hospital, where laboratory tests showed serum alfa-fetoprotein level of 1,522 ng/mL (normal value ≤20 ng/mL), β-hCG 518.9 mIU/mL (normal value ≤5 mIU/mL, chemiluminescent technology, Advia Centaur™ XP immunoassay system, Siemens, Erlangen, Germany), and CA 125 129 U/mL (normal value ≤35 U/mL). A chest computed tomography scan was negative.

The patient underwent cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy with pelvic lymphadenectomy, omentectomy, appendectomy, partial sigmoidectomy with anastomosis, and resection of abdominal and pelvic metastases, without residual visible metastases. The uterus measured 10 × 8 × 5 cm and the cavity was filled with a cauliflower-like tumor measuring 6 × 3 × 2.5 cm and containing areas of ulceration (see [Figure 1](#f1-ott-6-1515){ref-type="fig"}). This solid tumor had a grayish-white cut surface and moderate texture. Histopathologic examination of the uterine tumor revealed well to moderately differentiated endometrial adenocarcinoma with yolk sac tumor-like differentiation intraendometrially, with a close transition between the two components ([Figure 2](#f2-ott-6-1515){ref-type="fig"}). No trophoblastic component was found. The metastases were identical to the primary lesion on histology. The myometrium, cervix, appendix, bilateral adnexa, and iliac lymph nodes were negative for tumor. Periodic-acid Schiff stain was positive in yolk sac tumor cells. Immunohistochemical analysis revealed that both endometrial adenocarcinoma and yolk sac tumor components were positive for AE1/AE3. The yolk sac tumor component was strongly positive for alfa-fetoprotein, while the endometrial adenocarcinoma was relatively negative ([Figure 3](#f3-ott-6-1515){ref-type="fig"}). The endometrial adenocarcinoma component was positive for EMA, CA125, and CK7, suggesting epithelial neoplasms. There was focal positive staining for p53. Estrogen receptor and progesterone receptor status were both negative, as were hCG and β-hCG.

Two days after surgery, serum alfa-fetoprotein and β-hCG levels decreased dramatically to 166.4 ng/mL and 13.7 mIU/mL, respectively, and the CA125 level dropped into the normal range. Six courses of intravenous chemotherapy with paclitaxel 175 mg/m^2^ per day followed by carboplatin for an area under the concentration-time curve of 5 mg/mL per minute were administered every 21 days. Serum alfa-fetoprotein dropped to the normal range after three courses, while β-hCG fluctuated in the range of 5--20 mIU/mL despite two additional courses of chemotherapy with etoposide, methotrexate, actinomycin D, etoposide, and cisplatin[@b25-ott-6-1515] followed by two courses with bleomycin, etoposide, and platinum.[@b26-ott-6-1515] The persistent slightly elevated β-hCG was considered due to abnormal pituitary feedback, so chemotherapy was stopped. Unfortunately, β-hCG and alfa-fetoprotein rose again 2--3 months later. Despite salvage chemotherapy with two cycles of floxuridine, dactinomycin, etoposide, and vincristine,[@b27-ott-6-1515] serum alfa-fetoprotein reached 311.1 ng/mL and β-hCG reached 2,716.5 mIU/mL. After the final course with oxaliplatin 200 mg and cyclophosphamide 800 mg, the patient abandoned further treatment and was lost to follow-up.

Discussion
==========

Here we report a case of endometrial carcinoma with yolk sac tumor-like differentiation as well as elevated serum β-hCG level suggesting trophoblastic differentiation although there was a lack of histologic evidence. Yolk sac tumors and trophoblastic neoplasms are both malignant germ cell tumors, and when found simultaneously, mixed germ cell tumor is diagnosed, and usually within the gonads.[@b28-ott-6-1515] Primary extragonadal concurrent yolk sac tumors and trophoblastic neoplasms are extremely rare, but have been known to occur in the thyroid,[@b29-ott-6-1515] Barrett's esophagus,[@b30-ott-6-1515] and in gastric[@b31-ott-6-1515] and colon carcinoma.[@b32-ott-6-1515] The histogenetic mechanism for primary extragonadal germ cell tumors remains controversial.[@b7-ott-6-1515] The close transition from the endometrioid adenocarcinoma to the yolk sac tumor areas ([Figure 2](#f2-ott-6-1515){ref-type="fig"}) in the present case supports an origin involving aberrant differentiation of somatic cells. Mixed tumors with a germ cell tumor component usually manifest as tumors in corresponding organs; for instance the present case had a medical history of abnormal vaginal bleeding of 14 months' duration, which unfortunately was not paid enough attention. Unlike typical endometrial carcinoma, she was young and presented with peritoneal metastasis without myometrial infiltration or lymphadenopathy. Hence, histopathologic examination of specimens from diagnostic curettage and exploratory laparotomy are of great clinical importance in such circumstances.

Primary yolk sac tumors of the endometrium are extremely rare. To our knowledge, only nine cases have been reported in the literature ([Table 1](#t1-ott-6-1515){ref-type="table"}),[@b1-ott-6-1515]--[@b9-ott-6-1515] among which seven cases are pure yolk sac tumors and only two cases[@b6-ott-6-1515],[@b7-ott-6-1515] are in coexistence with endometrial carcinoma. All the patients presented with a medical history of abnormal vaginal bleeding and elevated serum alfa-fetoprotein levels before or immediately after surgery. Extragonadal germ cell tumors are diagnosed histopathologically. Yolk sac tumor presents variously under the microscope, and occasionally there is confusion in differentiating a microcystic or endodermal sinus-like structure from a clear cell uterine carcinoma and a papillary structure from uterine serous papillary carcinoma. In addition to morphologic differences, immunohistochemical staining is helpful. Yolk sac tumors are strongly positive for alfa-fetoprotein. In addition, serum alfa-fetoprotein determinations are important in the diagnosis of yolk sac tumors and monitoring metastasis or recurrence after therapy. Most of the reviewed cases experienced a reduction in serum alfa-fetoprotein after surgery and adjuvant therapy, as did our patient.

Yolk sac tumors usually occur in the gonads of young people.[@b1-ott-6-1515] In the previously published literature, cases with pure yolk sac tumors are younger (age range 27--49 years, mean 32.7 years) than those with mixed tumors (age range 59--65 years, mean 62 years). In the seven patients with pure yolk sac tumors, five[@b3-ott-6-1515]--[@b5-ott-6-1515],[@b8-ott-6-1515],[@b9-ott-6-1515] presented no metastasis (or not described) and no evidence of disease at last follow-up more than one year (6 year at most) after diagnosis. Among these five, two cases[@b8-ott-6-1515],[@b9-ott-6-1515] had a unilateral ovary or bilateral ovaries retained after surgery because they were young women, indicating a more favorable prognosis. In contrast with these cases, those with endometrial neoplasms with yolk sac tumor-like differentiation were all postmenopausal women, and presented with early metastasis to the liver, diaphragm, or abdominal lymph nodes. This second group of cases tends to have a worse prognosis. The case reported by Patsner[@b6-ott-6-1515] used a potential carcinogen (tamoxifen for prior breast cancer) and the tumor metastasized 19 months after diagnosis despite two surgeries and administration of combined chemotherapy and radiotherapy. The different components of the tumor have a transition zone, so erroneous differentiation of somatic cells was proposed as the histogenetic mechanism of the tumor cells, ie, the yolk sac tumor cells were derived from dedifferentiation or retrodifferentiation of somatic endometrial (tumor) cells. The present case had concurrent endometrioid adenocarcinoma and yolk sac tumor components in both primary and metastatic tumors, and metastasis occurred early. Despite multiple courses and regimens of chemotherapy, alfa-fetoprotein rose again 8 months postoperatively. These clinical and pathologic features strongly resemble the cases in the latter group mentioned above, except for the very young age of 28 years.

The present self-reported nulligravid case had elevated serum β-hCG level during her entire medical course, but no trophoblastic differentiation was observed under the microscope. Grenache et al[@b33-ott-6-1515] reported a similar case of endometrial adenocarcinoma without trophoblastic differentiation and with an elevated serum free β-hCG and no evidence of pregnancy. In their case, endometrial adenocarcinoma cells showed hCG immunoreactivity and were believed to produce free β-hCG. In the present case, however, the decrease in β-hCG following surgery and chemotherapy excluded the possibility of phantom β-hCG or β-hCG elevation associated with the testing method used. Given that the tumor cells seen were negative for hCG and β-hCG by immunohistochemical analysis, the authors believe that a trophoblastic component did exist, and the negative histology findings might be due to the chemotherapy before admission, and failure to get the positive section in pathological slice-making.

Endometrial neoplasms with trophoblastic differentiation are also very rare, with only 17 cases reported in the literature ([Table 2](#t2-ott-6-1515){ref-type="table"}).[@b10-ott-6-1515]--[@b24-ott-6-1515] These 17 patients are relatively older (age range 34--88 years, mean 65.4 years). All cases, including the present one, presented with abnormal genital bleeding except for one without description, and elevated serum or urinary β-hCG before or shortly after therapy, with a median serum β-hCG level of 3,050 mIU/mL, except one case with normal serum β-hCG first measured after histologic diagnosis of surgical specimens.[@b21-ott-6-1515] Most of the cases had been pregnant, so gestational trophoblastic neoplasms could not be excluded completely. However, Olson et al[@b23-ott-6-1515] reported a case with clonal evolution from endometrioid carcinoma to trophoblastic tumor proven by morphologic and molecular genetic analysis, suggesting great utility of this method. Endometrioid adenocarcinoma is the most frequently reported histologic type in the predominant component of the concurrent tumor, occurring in 12 of the reported cases, with serous papillary carcinoma in two cases and clear cell carcinoma in one case. Khuu et al[@b17-ott-6-1515] and Nguyen et al[@b18-ott-6-1515] reported two cases of malignant Müllerian mixed tumor containing an endometrioid adenocarcinomatous component with trophoblastic differentiation as well as a sarcomatous component. The median follow-up duration was 11 months, and at last follow-up, seven cases had died (follow-up 1.5--24 months), two were alive with disease (1 and 5 months), and five with relatively low initial serum β-hCG (median 283 mIU/mL) were alive without evidence of disease (6--50 months).

Horn et al[@b20-ott-6-1515] proposed two prognostically relevant types of endometrial carcinoma containing trophoblastic differentiation. One type presents with only a few syncytiotrophoblastic-like giant cells and the other with a notable extension of trophoblastic differentiation, resembling a choriocarcinoma. The latter type is associated with strongly elevated β-hCG, early metastasis, and often a fatal course. The present case presented with no observable trophoblastic cells and a moderately elevated β-hCG at admission, suggesting a more favorable prognosis according to Horn's proposition. However, despite the rapid decrease in β-hCG after hysterectomy, it remained slightly and persistently elevated and finally rose again to 2,716.5 mIU/mL. The patient was lost to follow-up 10 months after diagnosis, implying an unfavorable outcome.

Conclusion
==========

To the author's knowledge, endometrial adenocarcinoma associated with both yolk sac tumor-like differentiation and an elevated serum β-hCG level has never been reported in the literature. We present such a case and share our experiences in treatment. Unlike the reviewed cases of endometrial adenocarcinoma with a single germ cell tumor component, our patient was very young and presented with peritoneal metastasis early but without myometrial infiltration or lymphadenopathy. The histology of the metastases was identical to that of the primary tumor, with mixed components. The cytoreductive surgery and chemotherapy tend to show an effective immediate efficacy. The choice of subsequent chemotherapies was based on the major tumor component at each follow-up. However, the disease progressed rapidly and was resistant to salvage chemotherapy. Because medical history, gynecologic examination, and imaging results contribute little to early recognition of extragonadal germ cell tumors, histopathologic examination of specimens from diagnostic curettage and exploratory laparotomy are of great clinical significance in such conditions. Once diagnosed, serum alfa-fetoprotein and β-hCG determinations are important in monitoring metastasis or recurrence. The histogenetic mechanism is unclear, and further investigations with molecular genetic analysis are required.
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![Gross image of the uterus and tumor.](ott-6-1515Fig1){#f1-ott-6-1515}

![Mixed components: a close transition from the endometrial adenocarcinoma to the yolk sac tumor areas (hematoxylin and eosin, 100×).](ott-6-1515Fig2){#f2-ott-6-1515}

![Immunohistochemical staining results for alfa-fetoprotein confirm the existence of two components of endometrial adenocarcinoma and yolk sac tumor.](ott-6-1515Fig3){#f3-ott-6-1515}

###### 

Cases of primary yolk sac tumors of the endometrium

  Author                          Year   Case   Age (years)   Gravida and para   Serum AFP level                  Histopathology                                         Metastasis          Surgery                                                                                    Chemotherapy                                                                                Radiotherapy                     Follow-up time (months)   Status at last follow-up
  ------------------------------- ------ ------ ------------- ------------------ -------------------------------- ------------------------------------------------------ ------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- -------------------------------- ------------------------- --------------------------
  Pileri et al                    1980   1      28            2/2                380 ng/mL Post-operation         YST                                                    Liver, pelvic LNs   TAH, BSO                                                                                   VCR, vinblastine, CPA, ADM, MTX, 5-FU, medroxyprogesterone acetate                          −                                8                         DOD
  Clement et al[@b2-ott-6-1515]   1988   2      24            \>0/\>0            3,600 ng/mL Post-operation       YST                                                    Umbilicus           Supracervical HYS, BSO                                                                     VCR, Act-D, CPA                                                                             \+                               24                        DOD
  Ohta et al[@b3-ott-6-1515]      1988   3      27            0/0                1,580 ng/mL Pre-operation        YST                                                    ND                  TAH, BSO, OMT                                                                              VCR, Act-D, CPA                                                                             −                                14                        NED
  Joseph et al[@b4-ott-6-1515]    1990   4      42            5/5                18,530 ng/mL Pre-operation       YST                                                    None                TAH, BSO                                                                                   Vinblastine, BLM, CDDP                                                                      −                                24                        NED
  Spatz et al[@b5-ott-6-1515]     1997   5      49            1/1                Normal 3 weeks after operation   YST                                                    None                TAH, BSO, LD                                                                               Refused                                                                                     45 Gy on the pelvis              28                        NED
  Patsner[@b6-ott-6-1515]         2000   6      59            3/3                27,670 U/mL Post-operation       Adenocarcinoma, YST                                    Liver, diaphragm    TAH, BSO, LD, OMT                                                                          BEP(BLM, VP-16, CDDP), EP(VP-I6, CDDP)                                                      21 Gy by vaginal brachytherapy   19                        AWD
  Oguri et al[@b7-ott-6-1515]     2006   7      65            ND                 2,306 ng/mL Pre-operation        MMMT containing adenocarcinoma, stromal sarcoma, YST   LNs                 Modified radical HYS, BSO, LD                                                              PTX, CBDCA                                                                                  −                                ND                        Survived surgeries
  Rossi et al[@b8-ott-6-1515]     2011   8      30            ND                 1,762 ng/mL Pre-operation        YST                                                    None                TAH                                                                                        BEP (BLM, VP-16, CDDP)                                                                      −                                72                        NED
  Wang et al[@b9-ott-6-1515]      2011   9      29            2/1                3,593.4 ng/mL Pre-operation      YST                                                    None                Modified HYS with left adnexa resection, LD                                                VP-16, CBDCA BLM                                                                            −                                39                        NED
  Present                                10     28            0/0                1,522 ng/mL Post-chemotherapy    Adenocarcinoma, YST                                    Peritoneum          TAH, BSO, OMT, LD, appendectomy, partial resection of the sigmoid colon with anastomosis   PTX, ADM, CDDP, CBDCA, MTX, Act-D, VP-16, BLM, pingyangmycin, VCR, FUDR, oxaliplatin, CPA   −                                10                        AWD

**Abbreviations:** AFP, α-fetoprotein; YST, yolk sac tumor; LN, lymph node; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; VCR, vincristine; CPA, cyclophosphamide; ADM, adriamycin; MTX, methotrexate; 5-FU, 5-fluorouracil; DOD, dead from the disease; HYS, hysterectomy; Act-D, actinomycin-D; OMT, omentectomy; ND, not described; NED, no evidence of the disease; BLM, bleomycin; CDDP, cisplatin; Gy, gray; BEP, bleomycin, etoposide and platinum; MMMT, malignant mullerian mixed tumor; LD, lymphadenectomy; VP-16, etoposide; AWD, alive with disease; PTX, paclitaxel; CBDCA, carboplatin; FUDR, 5-fluoro-2′-deoxy-β-uridine.

###### 

Cases of endometrial neoplasm with trophoblastic differentiation

  Author                                 Year   Case   Age (years)   Gravida and para   Serum (S)/urinary (U) hCG level                          Concurrent endometrial tumor                                      Metastasis                                 Surgery                                                                   Chemotherapy                                                                                Radiotherapy        Follow-up time (mo)   Status at last follow-up
  -------------------------------------- ------ ------ ------------- ------------------ -------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------- --------------------- --------------------------
  Civantos and Rywlin[@b10-ott-6-1515]   1972   1      87            3/2                U hCG: 1,000 IU/24 hours Preradiotherapy                 SPC                                                               ND                                         --                                                                        --                                                                                          \+                  ND                    ND
  Savage et al[@b11-ott-6-1515]          1987   2      70            1/1                Unmeasured                                               AD                                                                Liver, kidneys, lungs, brain, peritoneum   TAH, BSO                                                                  Medroxyprogesterone, 5-FU, ADM, megestrol acetate                                           \+                  14                    DOD
  Pesce et al[@b12-ott-6-1515]           1991   3      78            ND/0               S β-hCG: 19,500 mIU/mL Pre-chemotherapy                  AD                                                                LNs                                        --                                                                        CDDP, BLM, oncovin (VCR)                                                                    −                   1.5                   DOD
                                                4      48            5/ND               S β-hCG: 3,050 mIU/mL Pre-operation                      AD                                                                Lungs                                      TAH                                                                       MTX; VP-16, BLM, CDDP                                                                       −                   ND                    ND
                                                5      63            Multi/multi        U hCG: 1,00,000 IU/24 hours Persistently until death     AD                                                                Peritoneum, lungs, liver                   TAH, BSO                                                                  --                                                                                          −                   14                    DOD
  Kalir et al[@b13-ott-6-1515]           1995   6      83            0/0                S hCG: \>1,00,000 mIU/mL Pre-operation                   AD                                                                Lungs                                      TAH, BSO                                                                  CDDP, VP-16                                                                                 −                   1                     AWD
  Black et al[@b14-ott-6-1515]           1998   7      88            ND/1               S hCG: 851 IU/L (estimated postoperatively)              Clear cell AD; focal endometrioid differentiation                 None                                       TAH, BSO                                                                  --                                                                                          50.4 Gy on pelvis   18                    Died from UTI
  Bradley et al[@b15-ott-6-1515]         1998   8      68            4/4                S β-hCG: 95 mIU/mL Pre-operation                         AD; focal squamous and clear cell differentiation                 LNs                                        TAH, BSO, OMT, LD                                                         Megestrol acetate; PTX, CBDCA                                                               −                   16                    NED
  Tunc et al[@b16-ott-6-1515]            1998   9      54            6/6                S β-hCG: 5,514 mIU/mL Pre-operation                      AD                                                                Retroperitoneal mass                       TAH, BSO                                                                  MTX, CPA, Act-D, VP-16, folinic acid                                                        −                   24                    DOD
  Khuu et al[@b17-ott-6-1515]            2000   10     71            0/0                S β-hCG: 283 mIU/mL Post-operation                       (Anterior) AD; (posterior) MMMT containing AD                     --                                         TAH, BSO, LD                                                              --                                                                                          −                   8                     NED
  Nguyen et al[@b18-ott-6-1515]          2000   11     34            0/0                S β-hCG: 32,000 mIU/mL Pre-operation                     MMMT containing AD, focal clear cell and serous differentiation   Lungs, brain, LNs                          TAH, BSO, OMT, LD                                                         PEB (BLM, VP-16, CDDP), EMA/CO (VP-16, MTX, Act-D, CPA, VCR), CDDP, PTX                     44 Gy on brain      7                     DOD
  Le Bret et al[@b19-ott-6-1515]         2005   12     54            4/1                S β-hCG: 13,87,205 IU/L Pre-operation                    AD                                                                Lungs                                      Colpohysterectomy, LD                                                     VP-16, CDDP                                                                                 45 Gy on pelvis     18                    NED
  Horn et al[@b20-ott-6-1515]            2006   13     61            3/3                S β-hCG: 2,25,000 IU/L Pre-operation                     SPC                                                               Lungs                                      TAH, BSO, LD                                                              MTX, EMA/CO (VP-16, MTX, Act-D, CPA, VCR)                                                   −                   3                     DOD
  Akbulut et al[@b21-ott-6-1515]         2008   14     42            ND/ND              S β-hCG: 1.74 mIU/mL Pre-operation                       AD                                                                None                                       TAH, BSO, appendectomy, OMT, LD                                           --                                                                                          −                   6                     NED
  Yamada et al[@b22-ott-6-1515]          2008   15     58            1/1                S β-hCG: 38 ng/mL Pre-operation                          AD                                                                Vaginal cuff                               TAH, BSO, LD                                                              CTP (CBDCA, THP, CPA); EMA/CO (VP-16, MTX, Act-D, CPA, VCR)                                 −                   50                    NED
  Olson et al[@b23-ott-6-1515]           2011   16     68            6/4                ND                                                       AD                                                                Axillary LN                                TAH, BSO                                                                  ND                                                                                          ND                  ND                    ND
  Wakahashi et al[@b24-ott-6-1515]       2012   17     85            5/2                S β-hCG: 8.0 ng/mL (normal, \<0.1 ng/mL) Pre-operation   AD with squamous differentiation                                  Peritoneum; Douglas pouch                  TAH, BSO                                                                  --                                                                                          −                   5                     AWD
  Present                                       18     28            0/0                S β-hCG: 518.9 mIU/mL Post-chemotherapy                  AD, YST                                                           Peritoneum                                 TAH, BSO, OMT, LD, appendectomy, partial sigmoidectomy with anastomosis   PTX, ADM, CDDP, CBDCA, MTX, Act-D, VP-16, BLM, pingyangmycin, VCR, FUDR, oxaliplatin, CPA   −                   10                    AWD

**Abbreviations:** hCG, human chorionic gonadotropin; SPC, serous papillary carcinoma; ND, not described; AD, adenocarcinoma; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; 5-FU, 5-fluorouracil; ADM, adriamycin; DOD, dead of the disease; LN, lymph node; CDDP, cisplatin; BLM, bleomycin; VCR, vincristine; MTX, methotrexate; VP-16, etoposide; AWD, alive with the disease; Gy, gray; UTI, urinary tract infection; OMT, omentectomy; LD, lymphadenectomy; PTX, paclitaxel; CBDCA, carboplatin; NED, no evidence of the disease; Act-D, actinomycin-D; MMMT, malignant mullerian mixed tumor; CPA, cyclophosphamide; THP, herarubicin; YST, yolk sac tumor; FUDR, 5-fluoro-2′-deoxy-β-uridine.
